ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 914,65
-0,88%
Dow Jones
38 225,66
0,85%
DAX
17 896,50
-0,14%
Brent Oil
83,685
0,17%
Bitcoin
58 800,72
0,97%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Cullinan Therapeutics Inc (CGEM)

  7. Cullinan Therapeutics Inc (CGEM) Actualités

CGEM Cullinan Therapeutics Inc

27,58
-0,52 (-1,85%)
Après les heures de négociation
Dernière mise à jour : 22:11:15
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Cullinan Therapeutics Inc CGEM NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,52 -1,85% 27,58 22:11:15
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
28,22 26,73 28,22 27,58 28,10
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
29/4/202413:00GLOBECullinan Therapeutics Announces Appointment of Mary Kay..
24/4/202416:09GLOBECullinan Therapeutics to Present Clinical Data from Phase 1..
16/4/202413:00GLOBECullinan Therapeutics Announces Strategic Expansion into..
16/4/202412:59GLOBECullinan Therapeutics Announces Oversubscribed $280 million..
14/3/202412:00GLOBECullinan Oncology Provides Corporate Update and Reports..
01/3/202413:00GLOBECullinan Oncology Announces U.S. FDA Clearance of..
27/2/202414:00GLOBECullinan Oncology to Participate in Upcoming Investor..
23/2/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202403:01EDGAR2Form SC 13G - Statement of acquisition of beneficial..
03/2/202403:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202422:43EDGAR2Form 144 - Report of proposed sale of securities
31/1/202401:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/1/202422:27EDGAR2Form 144 - Report of proposed sale of securities
24/1/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/1/202422:18EDGAR2Form 144 - Report of proposed sale of securities
08/1/202422:15EDGAR2Form 8-K/A - Current report: [Amend]
08/1/202415:12EDGAR2Form 8-K - Current report
22/12/202323:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/12/202323:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/12/202323:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/12/202323:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/12/202300:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/12/202300:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/12/202300:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/12/202300:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/12/202322:53GLOBECullinan Oncology to Present at the 42nd Annual J.P. Morgan..
14/12/202322:30GLOBECullinan Oncology Announces First Patient Dosed in Phase 1..
14/12/202302:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/12/202302:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/11/202313:22EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202313:10EDGAR2Form 8-K - Current report
08/11/202313:00GLOBECullinan Oncology Provides Corporate Update and Reports..
03/11/202317:01GLOBECullinan Oncology to Present Data Demonstrating Progress..
30/10/202313:00GLOBECullinan Oncology to Participate in Upcoming Investor..
06/9/202314:00GLOBECullinan Oncology to Participate in Upcoming Investor..
10/8/202313:44EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202313:07EDGAR2Form 8-K - Current report
10/8/202313:00GLOBECullinan Oncology Provides Corporate Update and Reports..
09/8/202313:00GLOBECullinan Oncology Announces First Patient Dosed in Phase 1..
03/8/202322:15PRNUSREZILIENT3 Global First-Line Trial of Zipalertinib Launched..
31/7/202314:00GLOBECullinan Oncology to Participate in Upcoming Investor..
06/7/202303:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/5/202323:00GLOBECullinan Oncology to Present First Monotherapy Clinical Data..
11/5/202322:01GLOBECullinan Oncology Provides Corporate Update and Reports..

Dernières Valeurs Consultées

NASDAQ
CGEM
Cullinan Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés